Libby Wirth, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 101 Willmar Ave Sw, Willmar, MN 56201 Phone: 320-214-6962 |
Gregory Whittemore Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2505 1st St S, Willmar, MN 56201 Phone: 320-235-3026 |
Nathan Goracke, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 301 Becker Ave Sw, Willmar, MN 56201 Phone: 320-231-4250 |
George Michael Cullina, PHARMD Pharmacist - Ambulatory Care Medicare: Not Enrolled in Medicare Practice Location: 101 Willmar Ave Sw, Willmar, MN 56201 Phone: 320-214-6962 |
Diann Somody Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1300 5th St Se, Willmar, MN 56201 Phone: 320-235-2506 Fax: 320-214-8673 |
Jamie Kalean Erickson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 101 Willmar Ave Sw, Willmar, MN 56201 Phone: 320-214-6962 |
News Archive
RedPath Integrated Pathology, Inc., a cancer molecular diagnostics company headquartered in Pittsburgh, PA, announced today that it has entered into a binding agreement to be acquired by ExonHit Therapeutics, S.A., a leading French diagnostics and therapeutics biotech company for an upfront payment of $12.5M in cash and $10M in stock, and starting in 2012, subsequent additional payment up to $9.5M dependent on the achievement of sales targets.
Formlabs, the designer and manufacturer of powerful and accessible 3D printing systems, has released a user story with Dr Sam Pashneh-Tala, Research Fellow at the University of Sheffield, who is leading pioneering tissue engineering techniques for creating complex artificial blood vessels with patient-specific shapes, powered by Formlabs SLA 3D printers.
In the last 50 years, modern medicine has made astounding advances in surgery, yet many of today's veterinary and human medicine students still hone basic surgical and suturing skills on carpet pads and pig's feet before transitioning to a live patient. An invention by Colorado State University veterinarians provides students with artificial body parts that look, feel, behave, and even bleed just like real skin, muscles and vessels.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD).
Tiny fibres used to strengthen everyday products such as bicycle frames and hockey sticks could pose health hazards to those involved in their manufacture.
› Verified 6 days ago